Range
264.35 - 270.37
Vol / Avg.
873.3K/990.3K
Div / Yield
-
52 Wk
223.25 - 468.55
Mkt Cap
39.5B
Payout Ratio
-
Open
269.38
P/E
25.34
EPS
3
Shares
149M
Outstanding
149M
Total Float
132.3M
load more
Sector: Health Care.Industry: Biotechnology
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Earnings

see more
Q3 2021Est.ActualSurprise
EPS4.1104.770 0.6600
REV2.670B2.779B109.000M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Biogen Questions & Anwsers

Q

How do I buy Biogen (BIIB) stock?

A

You can purchase shares of Biogen (NASDAQ: BIIB) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Biogen's (BIIB) competitors?

Q

What is the target price for Biogen (BIIB) stock?

A

The latest price target for Biogen (NASDAQ: BIIB) was reported by Cowen & Co. on October 21, 2021. The analyst firm set a price target for 375.00 expecting BIIB to rise to within 12 months (a possible 41.62% upside). 50 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Biogen (BIIB)?

A

The stock price for Biogen (NASDAQ: BIIB) is $264.8 last updated Fri Oct 22 2021 20:00:04 GMT+0000 (Coordinated Universal Time).

Q

Does Biogen (BIIB) pay a dividend?

A

There are no upcoming dividends for Biogen.

Q

When is Biogen (NASDAQ:BIIB) reporting earnings?

A

Biogen’s $Q3 earnings are confirmed for after-market on $October 20, 2021.

Q

Is Biogen (BIIB) going to split?

A

There is no upcoming split for Biogen.

Q

What sector and industry does Biogen (BIIB) operate in?

A

Biogen is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.